RESUMEN

Early discover of risk progression of invisible carcinomas is important for a prerequisite successful treatment. Here, we investigated whether concentration of human thymidine kinase 1 (HTK1) discover invisible malignant human tumours. The HTK1 concentration of tumour cellular based on HTK1 IgY-polyclonal-antibody (HTK1-IgY-pAb) was determined by using a novel automatic chemiluminescence analyser with sandwich biotin-streptavidin (SBSA) platform. Minimum number of cells able to be detected by this technology used cells with low and high concentration of HTK1. The limit visibility by tumour imaging is approximately 1 mm in diameter, corresponding to approximately 109 cells with a cell diameter of 1 µm. Based on a HTK1 standard curve and a molecular weight of HTK1 of 96 kD, the HTK1protein (HTK1p) concentration per cell was calculated to be 0.021 pg. Assuming 200 pg in total protein/cell, approximately 50 × 106 growing malignant cells in the body were calculated to releases HTK1 into 5-liter blood. A HTK1 values of 3.914, 0.435 and 0.009 pmol/L corresponds to 10 × 105, 2 × 105 and 1 × 105 growing malignant cells, respectively. The lowest detectable sensitivity of HTK1 is 0.009 pmol/L in 1 × 105 growing malignant cells and 0.01 pmol/L in blood serum, detectable in health screening. Comparing the novel automatic chemiluminescence analyser with the original ECL dot-blot assay using serum HTK1p (health screening, n = 265) showed high correlation (r = 0.8743, P < .000). In conclusion, the novel automatic chemiluminescence analyser with SBSA platform is a reliable method with high accuracy to determine carcinoma invisible.

Asunto(s)

Neoplasias , Timidina Quinasa , Humanos

RESUMEN

OBJECTIVE: To comprehensively evaluate the primary performance regarding the task of detecting thrombomodulin (TM), thrombin-antithrombin complex (TAT), plasmin-α2-plasmin inhibitor complex (PIC), and tissue plasminogen activator/plasminogen activator inhibitor-1 complex (t-PAIC) by Sysmex HisCL5000 high sensitivity chemiluminescence analyzer. METHODS: The performance of the chemiluminescence analyzer was evaluated according to the Clinical and Laboratory Standards Institute (CLSI) documents for in-batch precision, daytime precision, carryover rate, linearity, and reference range. RESULTS: The intra-batch and inter-day variation coefficients of the test items were all less than 5 %, and the contamination rate of each index was less than 10 %. The linear verification analysis showed that the correlation coefficients of TM, TAT, PIC, and t-PAIC were 0.9968, 0.9988, 0.9981, and 0.9930, respectively. The project recommended reference range was applicable to our laboratory. CONCLUSION: The high-sensitivity chemiluminescence analyzer has good performance in the detection of TM, TAT, PIC, and t-PAIC and is suitable for the detection of clinical specimens. HIPPOKRATIA 2022, 26 (2):78-82.

RESUMEN

Objective: Fractional exhaled nitric oxide (FeNO) is widely used as a biomarker of allergic airway inflammation. At present, both stationary chemiluminescence and portable electrochemical analyzers produced by different manufacturers are available. However, it remains debatable whether those analyzers are comparable to each other. We compare FeNO levels obtained by different analyzers.Methods: For the first study, 153 subjects were enrolled to compare differences in FeNO levels measured using three analyzers (NA623NP®, NObreath®, and NIOX MINO®) which were produced by different manufacturers. For the second study, 30 subjects were recruited to compare FeNO levels obtained by the two analyzers (NIOX MINO® and NIOX VERO®) produced by the same manufacturer. FeNO was measured twice using each analyzer in random order.Results: FeNO levels obtained using the NIOX MINO® and NObreath® were more variable than those measured using the NA623NP®. There were strong positive correlations in FeNO levels measured by the NA623NP®, NIOX MINO®, and NObreath® (p < 0.001). The NA623NP® and NIOX MINO® provided the highest and lowest FeNO levels, respectively; whereas, those obtained by NObreath® were intermediate. No significant differences were observed in FeNO levels obtained using the NIOX MINO® and NIOX VERO®.Conclusions: FeNO levels measured by the NIOX MINO® and NIOX VERO®, both of which were produced by the same manufacturer, have comparability. However, significant differences in FeNO levels exist when measured by analyzers manufactured by different manufacturers. This should be taken into account for FeNO measurement.

Asunto(s)

Asma/diagnóstico , Óxido Nítrico/análisis , Adulto , Anciano , Anciano de 80 o más Años , Pruebas Respiratorias/instrumentación , Estudios de Casos y Controles , Femenino , Voluntarios Sanos , Humanos , Masculino , Persona de Mediana Edad , Reproducibilidad de los Resultados

RESUMEN

Objective To evaluate the performance of the MAKER IS1200 automated chemiluminescence analyzer .Methods A series of experiments were designed to evaluate the precision ,reagent open bottle stability ,linearity range and reference interval of the MAKER IS1200 automated chemiluminescence analyzer in 8 items of hepatitis B 5 indexes ,AIDS ,hepatitis C and syphilis ac‐cording to the requirements of CLSI documents ,the detection results were performed the methodological comparison with those de‐tected by Abbott i2000 automated chemiluminescence analyzer .Results Except the total precision of HBEAG low value was slight‐ly higher than 15% of the judgment standard ,other indexes conformed to the requirements ;the open bottle stability of various items of reagent was better ;the quantitative item HBSAB had good linearity within the detection range (r2 >0 .95);in the verification of reference interval ,no outlier was found in each item ;in the methodological comparison ,the other items had good correlation with those detected by the ABBOTT i2000 except anti‐HCV .Conclusion The MAKER IS1200 automated chemiluminescence analyzer has good detection performance and meets the requirements of immunoassay detection in laboratory work .

RESUMEN

Objective To investigate the FSH/LH ratio in the evaluation of perimenopausal ovarian function in order to conduct better prevention and treatment of perimenopausal women diseases and preventive measures.Methods 42 perimenopausal women were selected as the research subjects from January 2013 to January 2014,among them,23 women aged 45 - 1,the study group 2 accounted for 68.42%,the study group 1 accounted for 39.13% and the control group accounted for 9.09%,there was statistically significant difference among 3 groups(P <0.05).Conclusion The serum FSH/LH ratio can be used as a reliable index for evaluating the perimenopausal ovarian function.

RESUMEN

Objective To study the results comparability of two kinds of different chemiluminescence systems(Antu chemilumi-nescence analyzer ADC CLIA 400 and Siemens centaur xp)in the detection of tumor markers.Methods The tumor markers were detected in 50 specimens by using the Antu chemiluminescence analyzer ADC CLIA 400 and the Siemens centaur xp chemilumines-cence analyzer respectively.Then the results were analyzed and compared.Results The quantitative analysis results on the serum specimens showed that there was no significant difference in the detection results between the two kinds of detection system(P >0.05).The correlation coefficients of 5 test items between the two kinds of detection system were more than 0.836,suggesting a good correlation between the two kinds of method.The accuracy and repeatability of the Siemens centaur xp chemiluminescence ana-lyzer were higher than those of the Antu chemiluminescence analyzer ADC CLIA 400 in detecting the tumor markers.Conclusion The Siemens centaur xp chemiluminescence analyzer is better than the Antu chemiluminescence analyzer ADC CLIA 400 in detec-ting the tumor immune markers.